Pfizer (NYSE:PFE) received a $41.00 target price from equities research analysts at Morgan Stanley in a research note issued to investors on Friday, January 5th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price would suggest a potential upside of 8.47% from the company’s previous close.
Several other equities analysts have also recently weighed in on the company. UBS Group set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Friday, November 10th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target for the company in a report on Thursday, November 23rd. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $38.50.
Shares of Pfizer (NYSE:PFE) opened at $37.80 on Friday. Pfizer has a 12-month low of $30.93 and a 12-month high of $39.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market capitalization of $232,586.80, a PE ratio of 15.61, a price-to-earnings-growth ratio of 2.40 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the firm earned $0.47 EPS. The firm’s revenue was up .6% compared to the same quarter last year. sell-side analysts expect that Pfizer will post 2.6 EPS for the current fiscal year.
Pfizer announced that its board has approved a share buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer in the 2nd quarter valued at $103,000. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $120,000. Finally, Americafirst Capital Management LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at $127,000. Hedge funds and other institutional investors own 69.87% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Pfizer (PFE) Given a $41.00 Price Target by Morgan Stanley Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/31/morgan-stanley-reiterates-41-00-price-target-for-pfizer-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.